BETA

IPO registrations (S-1, F-1) · Registrants

HUMANIGEN, INC

SEC CIK
1293310 · filings on EDGAR ↗
Former names
KALOBIOS PHARMACEUTICALS INC (2004–2017)
Registration
Form S-1, first filed 2012-10-05, last 2020-08-03; 4 initial registrations, 6 amendments
Outcome
Final prospectus filed 2013-02-01; declared effective 2013-01-31
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
830 MORRIS TURNPIKE, 4TH FLOOR, Short Hills, NJ 07078
EIN
77-0557236
EDGAR entity type
operating
Insiders and CEO pay
HUMANIGEN, INC on the corporate pages

Offering terms

Proposed price range
$8.00–$9.00 per share (S-1/A filed 2013-01-30)
Final price
$8.00 per share, within the range (424B4 filed 2013-02-01, an initial public offering)
Shares sold
8,750,000
Gross proceeds
$70,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol KBIO
Lead underwriters
Leerink Partners
Syndicate
William Blair; Needham & Company

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 23

FiledFormWhat it isName as filedEDGAR
2012-10-05S-1S-1 (registration)KALOBIOS PHARMACEUTICALS INC0001193125-12-415623 ↗
2012-11-16S-1/AS-1/A (amendment)KALOBIOS PHARMACEUTICALS INC0001193125-12-474207 ↗
2013-01-15S-1/AS-1/A (amendment)KALOBIOS PHARMACEUTICALS INC0001193125-13-012948 ↗
2013-01-30S-1/AS-1/A (amendment)KALOBIOS PHARMACEUTICALS INC0001193125-13-029265 ↗
2013-01-31S-1MEFS-1MEF (added securities)KALOBIOS PHARMACEUTICALS INC0001193125-13-031361 ↗
2013-01-31EFFECTEFFECT (declared effective)KALOBIOS PHARMACEUTICALS INC9999999995-13-000343 ↗
2013-02-01424B4424B4 (final prospectus)KALOBIOS PHARMACEUTICALS INC0001193125-13-034771 ↗
2013-09-18EFFECTEFFECT (declared effective)KALOBIOS PHARMACEUTICALS INC9999999995-13-002707 ↗
2017-03-17S-1S-1 (registration)KALOBIOS PHARMACEUTICALS INC0001214659-17-002051 ↗
2017-07-05S-1/AS-1/A (amendment)KALOBIOS PHARMACEUTICALS INC0001214659-17-004324 ↗
2017-07-14EFFECTEFFECT (declared effective)KALOBIOS PHARMACEUTICALS INC9999999995-17-001819 ↗
2018-04-26EFFECTEFFECT (declared effective)HUMANIGEN, INC9999999995-18-000930 ↗
2019-11-20S-1S-1 (registration)HUMANIGEN, INC0001214659-19-007319 ↗
2019-12-02EFFECTEFFECT (declared effective)HUMANIGEN, INC9999999995-19-002728 ↗
2020-04-06EFFECTEFFECT (declared effective)HUMANIGEN, INC9999999995-20-000686 ↗
2020-06-15S-1S-1 (registration)HUMANIGEN, INC0001214659-20-005577 ↗
2020-06-23EFFECTEFFECT (declared effective)HUMANIGEN, INC9999999995-20-001504 ↗
2020-07-09S-1/AS-1/A (amendment)HUMANIGEN, INC0001214659-20-006234 ↗
2020-08-03S-1/AS-1/A (amendment)HUMANIGEN, INC0001214659-20-006716 ↗
2020-08-05EFFECTEFFECT (declared effective)HUMANIGEN, INC9999999995-20-002027 ↗
2020-09-14EFFECTEFFECT (declared effective)HUMANIGEN, INC9999999995-20-002442 ↗
2020-11-19EFFECTEFFECT (declared effective)HUMANIGEN, INC9999999995-20-003233 ↗
2022-04-14EFFECTEFFECT (declared effective)HUMANIGEN, INC9999999995-22-000982 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2013-01-30S-1/Aregistration statement$8.00–$9.00$9.008,250,000$74,250,000Nasdaq KBIO3primary document; range, price sentence, shares headline, proceeds computed, cover names 3document ↗
2013-02-01424B4final prospectus$8.008,750,000$70,000,000Nasdaq KBIO3primary document; price sentence, shares headline, proceeds table, cover names 3document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
5AM CO INVESTORS LLCTenPercentOwner22012–2013
5AM Partners LLCTenPercentOwner32012–2013
5AM VENTURES LLCTenPercentOwner22012–2013
Alloy Annex I, LLCTenPercentOwner22012–2013
Alloy Annex I, L.P.TenPercentOwner22012–2013
Alloy Corporate 2000, L.P.TenPercentOwner22012–2013
Alloy Investors 2000, L.P.TenPercentOwner22012–2013
Alloy Partners 2000, L.P.TenPercentOwner22012–2013
Alloy Ventures 2000, LLCTenPercentOwner22012–2013
Alloy Ventures 2000, L.P.TenPercentOwner22012–2013
Azan AlainTenPercentOwner22012–2013
BAXTER INTERNATIONAL INCTenPercentOwner22012–2013
Cooper Jeffrey HOfficerChief Financial Officer22012–2013
DEVELOPMENT BANK OF JAPAN INC.TenPercentOwner32012–2013
EDB Investments Pte Ltd.TenPercentOwner22012–2013
EVNIN LUKETenPercentOwner22012–2013
GADICKE ANSBERTTenPercentOwner22012–2013
GALAKATOS NICHOLASTenPercentOwner22012–2013
HEALY JAMESDirector; Director,TenPercentOwner42012–2013
HENNER DENNISDirector,TenPercentOwner32012–2013
LEHMAN BROTHERS HOLDINGS INC. PLAN TRUSTTenPercentOwner12012
LOVE TED WDirector52012–2015
LYONS GARY ADirector42012–2015
Molfino NestorOfficerChief Medical Officer32012–2014
MPM Asset Management Investors 2005 BVIII LLCTenPercentOwner32012–2013
MPM BIOVENTURES III GMBH & CO. Beteiligungs KGTenPercentOwner32012–2013
MPM BIOVENTURES III GP L.P.TenPercentOwner32012–2013
MPM BIOVENTURES III LLCTenPercentOwner32012–2013
MPM BIOVENTURES III L.P.TenPercentOwner32012–2013
MPM BIOVENTURES III PARALLEL FUND, L.P.TenPercentOwner32012–2013
MPM BIOVENTURES III-QP L.P.TenPercentOwner32012–2013
MPM BioVentures Strategic Fund LPTenPercentOwner32012–2013
POWELL MICHAELTenPercentOwner22012–2013
Pritchard DavidDirector,OfficerChief Executive Officer32012–2014
SanofiOther; TenPercentOwner22012–2013
Shochat DanTenPercentOwner12012
SIMON NICHOLAS J IIITenPercentOwner22012–2013
SINGAPORE BIO INNOVATIONS PTE LTDTenPercentOwner22012–2013
Smith BrigitteDirector52012–2013
Sofinnova Management V 2005, LLCTenPercentOwner32012–2013
Sofinnova Management V LLCTenPercentOwner32012–2013
SOFINNOVA VENTURE AFFILIATES V LPTenPercentOwner32012–2013
SOFINNOVA VENTURE PARTNERS V LPTenPercentOwner32012–2013
SOFINNOVA VENTURE PRINCIPALS V LPTenPercentOwner32012–2013
STEINMETZ MICHAELTenPercentOwner22012–2013
WHEELER KURTTenPercentOwner22012–2013
Yarranton Geoffrey ThomasOfficerChief Scientific Officer42012–2015
WITHY RAYMOND MDirector42012–2015
GBS Bioventures II A/CTenPercentOwner32012–2013
GBS Venture Partners Pty, LtdTenPercentOwner32012–2013
Genesis FundTenPercentOwner22012–2013
GILBERT DENISEDirector42012–2015
Mitsubishi UFJ Capital II, Limited PartnershipTenPercentOwner22012–2013
Lehman Brothers Holdings Inc.Other12013
Joseph DonaldOfficerChief Legal Officer42013–2015
LAWLIS V BRYANDirector32013–2014
CROSS HERBOfficerChief Financial Officer152013–2015
Smaldone Alsup LaurieDirector42013–2015
BAFFI ROBERTDirector32014–2015
MARTELL RONDirector; Director,OfficerExecutive Chairman82015
Anthion Partners II LLCOther; TenPercentOwner72015
Moradi DavidDirector,TenPercentOwner; Other; TenPercentOwner52015
Shkreli MartinDirector,Officer,TenPercentOwner; TenPercentOwnerChief Executive Officer62015–2016
BIESTEK MAREKDirectorOther; Other42015
Fernandez Thomas EdwardDirector22015
Harrison Michael WayneDirector22015
CHASE ANTHONY RDirector12015
BARLIANT RONALDDirector182016–2022
Durrant CameronDirector; Director,OfficerChairman and CEO; Chief Executive Officer232016–2022
Witter Dean IIIOfficerInterim Chief Financial Ofcr12016
BLACK HORSE CAPITAL LPTenPercentOwner172016–2023
BLACK HORSE CAPITAL MANAGEMENT LLCTenPercentOwner192016–2023
Black Horse Capital Master Fund Ltd.TenPercentOwner172016–2023
Chappell DaleDirector,Officer,TenPercentOwner; Director,TenPercentOwner; Officer,TenPercentOwner; TenPercentOwnerChief Scientific Officer252016–2023
Cheval Holdings, Ltd.TenPercentOwner192016–2023
MORRIS TIMOTHY EDirector; OfficerCOO and CFO72016–2022
Friedberg Ezra MDirector22016
NOMIS BAY LTD.TenPercentOwner272016–2021
Lam MorganOfficerChief Scientific Officer32016–2017
Tousley David L.OfficerInterim CFO; See Remarks42016–2020
Boehm Rainer J.Director142018–2022
Jester J GregoryOfficerChief Financial Officer42018–2019
Savage Robert G.Director92018–2020
Buxton CherylDirector72019–2022
Jordan Edward P.OfficerChief Commercial Officer92020–2022
Kilcoyne AdrianOfficerChief Medical Officer82021–2022
Hohneker JohnDirector42021–2022
Xie Yili KevinDirector42021–2022

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2019-11-22HUMANIGEN, INCPharmaceuticals$20,494,614$494,61411
2019-05-07HUMANIGEN, INCPharmaceuticals$5,000,000$1,300,000111
2017-09-05HUMANIGEN, INCPharmaceuticals$15,015,000$15,00011
2016-07-15KALOBIOS PHARMACEUTICALS INCPharmaceuticals$12,150,000$12,150,00081
2016-01-06KALOBIOS PHARMACEUTICALS INCPharmaceuticals$8,818,000$8,218,000181

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationHUMANIGEN, INC.CAState business registriesEIN (EXACT, as the state registration reports it)
Form D issuerHUMANIGEN, INCCAForm D private offeringsCIK (EXACT)
SEC filerHUMANIGEN, INCSEC filers (EDGAR)CIK (EXACT)
Form 5500 plan sponsorHUMANIGEN, INC.EIN (EXACT)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, NJ first:

More with this interest.

In other datasets, the same topic (Health) in NJ:

Interests: Pharmaceutical Preparations · Health